2024-511526-31-00CompletedPhase 1
A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteers
Source: EU CTIS (euclinicaltrials.eu) · Last updated 13 Aug 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- First submitted
- 7 May 2024
- Start date
- 20 Aug 2024
- Lead sponsor
- Celon Pharma S.A.
- EU CT number
- 2024-511526-31-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 38
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bioresearch Group Sp. z o.o. | Warsaw | Poland | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.